ICH Q3E EWG Work Plan *February 08, 2025*

Topic Adoption date: *June 2019*

Rapporteur: Ms. Patricia Parris, PhRMA

Regulatory Chair: Dr. Jason Rodriguez, FDA, United States

Last Face-to-Face Meeting: Montreal, Canada, November 2024

1. Key milestones

1.a. Current status of key milestones

Past		
completion date	Milestone	
Jun. 2019	Topic was endorsed	
Jul. 2020	Final Concept Paper and Business Plan Endorsed	
Jun. 2023	ICH funding approved for Threshold Project and 1-year extension from vendor contract approval	
Sep. 2023	ELSIE MOU Finalized and Signed	
Oct. 2023	All three vendor contracts approved; Safety and Threshold Project Team meet in Prague, CR	
Nov. 2024	Quality/Chemistry and Safety subteams topics drafted for training materials	

1.b. Key Deliverables

Approval Date	Deliverable	
Jul. 2020	Q3E Guideline for Extractables and Leachables (E&L).	
Jun. 2023	Threshold Project - PDEs generation	

1.c. Future anticipated key milestones

Expected future completion date	Milestone	
May. 2025	EWG meeting in Madrid to:	
	Reach consensus on technical document	
Mar. 2025	Begin PWP consultation (1 month)	
Jun. 2025	Step 1 Sign-off, Step 2a/b endorsement	
Nov. 2025	End of Public consultation period	

2. Timeline for specific tasks

Beginning date	End date	Task / Activity	Details
Jun. 2023	May. 2025	 Threshold Project Ongoing peer reviews and EWG adoption of PDEs drafted by internal and external resources 	 Critical review of additional PDEs generated by internal and external resources Real time distribution analysis with peer reviewed PDEs Draft manuscripts: Database development and chemical characterization/prioritization; PDE methodology and QT derivation
Jun. 2024	May. 2025	Technical Document Integrate learning from Threshold Project into safety assessment strategy Align all aspects of the integrated draft guideline Format draft guideline per ICH template	 Define QT values based on threshold project data Develop content that harmonizes issues raised in the Concept Paper